ACARIX Stock Overview
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Acarix AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.23 |
| 52 Week High | kr0.64 |
| 52 Week Low | kr0.17 |
| Beta | 1.38 |
| 1 Month Change | -9.88% |
| 3 Month Change | 17.54% |
| 1 Year Change | -54.59% |
| 3 Year Change | -88.32% |
| 5 Year Change | -95.37% |
| Change since IPO | -98.57% |
Recent News & Updates
Shareholder Returns
| ACARIX | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -5.1% | 3.3% | -0.7% |
| 1Y | -54.6% | -61.4% | 4.4% |
Return vs Industry: ACARIX exceeded the Swedish Medical Equipment industry which returned -61.4% over the past year.
Return vs Market: ACARIX underperformed the Swedish Market which returned 4.4% over the past year.
Price Volatility
| ACARIX volatility | |
|---|---|
| ACARIX Average Weekly Movement | 13.2% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ACARIX's share price has been volatile over the past 3 months.
Volatility Over Time: ACARIX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 20 | Aamir Mahmood | www.acarix.com |
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out in Sweden and internationally. It offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced AI to analyze the patient's coronary blood flow. The company was founded in 2009 and is headquartered in Malmö, Sweden.
Acarix AB (publ) Fundamentals Summary
| ACARIX fundamental statistics | |
|---|---|
| Market cap | kr184.18m |
| Earnings (TTM) | -kr77.84m |
| Revenue (TTM) | kr6.24m |
29.5x
P/S Ratio-2.4x
P/E RatioIs ACARIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACARIX income statement (TTM) | |
|---|---|
| Revenue | kr6.24m |
| Cost of Revenue | kr944.00k |
| Gross Profit | kr5.30m |
| Other Expenses | kr83.14m |
| Earnings | -kr77.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 84.87% |
| Net Profit Margin | -1,247.22% |
| Debt/Equity Ratio | 0% |
How did ACARIX perform over the long term?
See historical performance and comparison